Drug Design and Optimization
In order to combat the increasing number of resistant pathogens, the development of new anti-infective drugs is an important goal for pharmaceutical research. Efficient medications with novel modes-of-action to fight infectious diseases are urgently needed. Below, you may read more about the design, identification and optimisation of new drug candidates. This group is located at the Helmholtz Institute for Pharmaceutical research Saarland (HIPS).
The opportunity to actively participate in the development of new drugs greatly intrigues me.
Rolf W. Hartmann studied chemistry at University of Technology, Munich and pharmaceutical sciences at the Ludwig-Maximilian University Munich. In 1981, he got his PhD in pharmaceutical chemistry in the area of drug design at the University of Regensburg. Since then, he has remained faithful to this field of research. He was initially engaged as a postdoctoral researcher at the Max-Planck-Institute for Experimental Endocrinology in Hannover.
In 1987, Rolf W. Hartmann completed his habilitation thesis for pharmaceutical chemistry at the University of Regensburg and in the following year, he was appointed as a professor at the Freie Berlin Universität.
Since 1989, he is holding a chair of professor for pharmaceutical chemistry at the Saarland University and has refused professorships of other universities and offers by pharmaceutical industry. Moreover, Rolf W. Hartmann is a member of many editorial boards and of several scientific journals, a referee for numerous national and international funding organizations and the co-founder of Pharmacelsus GmbH, ElexoPharm GmbH and PharmaBioTec GmbH at Saarbrücken.
For his distinguished research, Rolf W. Hartmann was honored with the Friedrich-Georg-Zimmermann Award for Cancer Research (1982) and the Phoenix-Pharmacy Research Award (1999).
Since 2009, he is head of the Department of Drug Design and Optimization of the recently established Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS).
Bachelor & Master
Are you interested in a bachelor or master thesis? We are looking forward to your request!
- Kündigung für Biofilm-WGs – Pharmazeuten des HIPS stören BakteriengemeinschaftenBakterien haben einen ausgeprägten Gemeinschaftssinn und verschanzen sich gerne in schleimigen Biofilmen. Etwa 60 Prozent aller bakteriellen Infektionen lösen inzwischen Biofilme aus. Ein besonders geselliger Keim ist Pseudomonas aeruginosa. Er ist besonders für Mukoviszidose-Patienten gefährlich. Wissenschaftler am Helmholtz-Institut für Pharmazeutische Forschung Saarland suchen nach Wegen, seine Biofilme aufzulösen – damit Medikamente wirken können. Begleiten Sie Anke Steinbach in Ihre Labore...